| Combination of | |
|---|---|
| Sitagliptin | Dipeptidyl peptidase-4 inhibitor |
| Metformin | Biguanide |
| Clinical data | |
| Trade names | Janumet, Januet, others |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Sitagliptin/metformin, sold under the brand nameJanumet among others, is afixed-dose combinationanti-diabetic medication used to treattype 2 diabetes.[10] It may be used in those whose blood sugar is not controlled withmetformin and asulfonylurea.[10][11] It is takenby mouth.[10]
Common side effects include diarrhea, headache, and upper respiratory tract infections.[5] Serious side effects may includelactic acidosis,pancreatitis,low blood sugar,heart failure, joint pain, andallergic reactions.[5] It has not been properly studied in women who arepregnant orbreastfeeding.[1] It containssitagliptin (adipeptidyl peptidase-4 inhibitor) andmetformin (abiguanide).[5]
The combination was approved for medical use in the United States in 2007.[5] In 2022, it was the 182nd most commonly prescribed medication in the United States, with more than 2 million prescriptions.[12][13] It is available as a generic medication.[14][15]
In the United States, sitagliptin/metformin isindicated as an adjunct to diet and exercise to improveglycemic control in adults withtype 2 diabetes.[5][6]
In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with asulfonylurea as an adjunct to diet and exercise "in people inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea; as triple combination therapy with aperoxisome proliferator-activated receptor (PPAR) agonist (i.e., athiazolidinedione) as an adjunct to diet and exercise in people inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist; and as add-on toinsulin as an adjunct to diet and exercise to improve glycemic control in people when stable dosage of insulin and metformin alone do not provide adequate glycemic control."[7]
In December 2020, the U.S.Food and Drug Administration (FDA) approved labeling changes stating that Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride), and Janumet XR (sitagliptin and metformin hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in children aged 10 to 17 with type 2 diabetes.[16] The drugs are approved to improve blood sugar control in adults aged 18 and older with type 2 diabetes.[16]
As of 2018, the combination is marketed under several brand names, including Efficib,[8] Janmet, Januet, Janumet, Jznumet, Ristaben Met, Ristfor, Siglimet, Sitamet, Sitar-M, Sliptin-M, Treviamet, Velmetia, Istamet, Emsita, Sitaglyn, Sitazit-M, and Zaxoran.[17]
This article incorporates text from this source, which is in thepublic domain.